Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;30(4):398-399.
doi: 10.18553/jmcp.2024.30.4.398.

THE AUTHORS RESPOND

Xiao Xu  1 , Rohit Katial  2 , Caroline Schaefer  3 , Agota Szende  4 , Eduardo Genofre  5 , Yen Chung  5
Affiliations

THE AUTHORS RESPOND

Xiao Xu et al. J Manag Care Spec Pharm. 2024 Apr.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Xu X, Schaefer C, Szende A, Genofre E, Katial R, Chung Y. A. cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective. J Manag Care Spec Pharm. 2023;29(11):1193-204. doi:10.18553/jmcp.2023.23034 - PMC - PubMed
    1. Institute for Clinical and Economic Review. Biologic therapies for treatment of asthma associated with type 2 inflammation: Effectiveness, value, and value-based price benchmarks. 2022. Accessed December 8, 2022. https://icer.org/wp-content/uploads/2020/10/Asthma-Revised-Report-FOR-PU...
    1. Akenroye A, Lassiter G, Jackson JW, et al. . Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022;150(5):1097-105.e12. doi:10.1016/j.jaci.2022.05.024 - PMC - PubMed
    1. Bourdin A, Korn S, Chupp GL, et al. . Integrated safety and efficacy among patients with severe asthma receiving benralizumab for up to five years. Am J Respir Crit Care Med. 2021;203:A1205. doi:10.1016/j.jaip.2021.07.058
    1. Chung Y, Katial R, Mu F, et al. . Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022;128(6):669-76. doi:10.1016/j.anai.2022.02.017 - PubMed

LinkOut - more resources